Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The Zepbound label itself directs that treatment response and tolerability be considered when selecting the maintenance dosage, which presupposes ongoing review
In a recent Phase 2 study presented in June 2025, combining it with semaglutide (the active ingredient in Wegovy) led to remarkable outcomes for participants with obesity: An average weight loss of 22% over 72 weeks (compared to 16% with semaglutide alone) About 93% of that loss coming from fat mass, with minimal impact on lean muscle A 58% drop in visceral fat (versus 36% with semaglutide alone) All achieved without requiring dietary or exercise modifications This stands out because typical weight-loss drugs, like GLP-1 agonists, often result in losing both fat and musclea downside, since muscle boosts metabolism and supports overall health as we age
Free delivery
GLP-1 constipation
US$ 25.76
US$ 23.25
US$ 26.48
US$ 20.78
US$ 27.82
US$ 20.70
US$ 29.83
US$ 24.24
US$ 20.16
US$ 21.93
